iHealthScreen Awarded US Patent on Glaucoma Detection Based on AI and Color Fundus Imaging

iHealthScreen was awarded a full US patent by USPTO on March 26, 2024 for the iPredict glaucoma detection model. The iPredict is designed to provide a fully automated detection report for glaucoma, which can be implemented in the primary care settings for screening and detection of early-stage glaucoma.

When high-resolution images of a patient’s eyes have been captured using a color fundus camera and submitted to the iPredict AI System, the glaucoma detection results are available in a fully automated report in less than 60 seconds. The entire test, which includes color retinal imaging and the automated AI-based glaucoma report generation, can easily and reliably be completed within 5 minutes, according to iHealthScreen.

Glaucoma detection offers an overall accuracy of 94.3% for identifying an individual with glaucoma. iPredict-glaucoma report will indicate referable (i.e., early to severe glaucoma) or non-referable glaucoma (not glaucoma). For referable glaucoma subjects, patients will be referred to the glaucoma specialists.

The company also has AI-based screening tools for early diagnosis of diabetic retinopathy, AMD and glaucoma which are CE certified, MHRA/UK and TGA/Australian health approved.

If referable stage disease is detected for any of these conditions, the iPredict automated report recommends a visit to an ophthalmologist for appropriate treatment. Otherwise, in accordance with standards of care, a follow-up visit is suggested (example, screening again in one year).

iPredict is indicated for use by healthcare providers in clinics, hospitals, or other healthcare facilities to automatically detect DR, AMD, and glaucoma suspects.